Skip to main content
PMC home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001 Nov-Dec;7(6):996–1003. doi: 10.3201/eid0706.010613

Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia.

A Hakanen 1, P Kotilainen 1, P Huovinen 1, H Helenius 1, A Siitonen 1
PMCID: PMC2631904  PMID: 11747728

Abstract

During 1995 to 1999, we collected 1,210 Salmonella isolates; 629 were from Finnish travelers returning from abroad. These isolates were tested for susceptibility by determining MICs to ciprofloxacin, nalidixic acid, and seven additional antimicrobial agents. From 1995 to 1999, the annual proportion of reduced ciprofloxacin susceptibility (MIC > 0.125 microg/mL) among all travelers' isolates increased from 3.9% to 23.5% (p<0.001). The increasing trend was outstanding among the isolates from Southeast Asia; isolates from Thailand alone increased from 5.6% to 50.0% (p<0.001). The reduced fluoroquinolone susceptibility was nonclonal in character and significantly associated with multidrug resistance. A point mutation in the quinolone resistance-determining region of gyrA was present in all isolates with reduced susceptibility. These data provide further evidence for the rapid spread of multidrug-resistant pathogens from one continent to another.

Full Text

The Full Text of this article is available as a PDF (68.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asperilla M. O., Smego R. A., Jr, Scott L. K. Quinolone antibiotics in the treatment of Salmonella infections. Rev Infect Dis. 1990 Sep-Oct;12(5):873–889. doi: 10.1093/clinids/12.5.873. [DOI] [PubMed] [Google Scholar]
  2. Brown J. C., Thomson C. J., Amyes S. G. Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J Antimicrob Chemother. 1996 Feb;37(2):351–356. doi: 10.1093/jac/37.2.351. [DOI] [PubMed] [Google Scholar]
  3. D'Alessio D. J., Olexy V. M., Jackson G. G. Oxolinic acid treatment of urinary-tract infections. Antimicrob Agents Chemother (Bethesda) 1967;7:490–496. [PubMed] [Google Scholar]
  4. Frost J. A., Kelleher A., Rowe B. Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991-1994. J Antimicrob Chemother. 1996 Jan;37(1):85–91. doi: 10.1093/jac/37.1.85. [DOI] [PubMed] [Google Scholar]
  5. Garau J., Xercavins M., Rodríguez-Carballeira M., Gómez-Vera J. R., Coll I., Vidal D., Llovet T., Ruíz-Bremón A. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999 Nov;43(11):2736–2741. doi: 10.1128/aac.43.11.2736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Giraud E., Brisabois A., Martel J. L., Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob Agents Chemother. 1999 Sep;43(9):2131–2137. doi: 10.1128/aac.43.9.2131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Glynn M. K., Bopp C., Dewitt W., Dabney P., Mokhtar M., Angulo F. J. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med. 1998 May 7;338(19):1333–1338. doi: 10.1056/NEJM199805073381901. [DOI] [PubMed] [Google Scholar]
  8. Hakanen A., Kotilainen P., Jalava J., Siitonen A., Huovinen P. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol. 1999 Nov;37(11):3572–3577. doi: 10.1128/jcm.37.11.3572-3577.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hakanen A., Siitonen A., Kotilainen P., Huovinen P. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J Antimicrob Chemother. 1999 Jan;43(1):145–148. doi: 10.1093/jac/43.1.145. [DOI] [PubMed] [Google Scholar]
  10. Herikstad H., Hayes P., Mokhtar M., Fracaro M. L., Threlfall E. J., Angulo F. J. Emerging quinolone-resistant Salmonella in the United States. Emerg Infect Dis. 1997 Jul-Sep;3(3):371–372. doi: 10.3201/eid0303.970316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hoge C. W., Bodhidatta L., Tungtaem C., Echeverria P. Emergence of nalidixic acid resistant Shigella dysenteriae type 1 in Thailand: an outbreak associated with consumption of a coconut milk dessert. Int J Epidemiol. 1995 Dec;24(6):1228–1232. doi: 10.1093/ije/24.6.1228. [DOI] [PubMed] [Google Scholar]
  12. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  13. Launay Odile, Nguyen Van Jean-Claude, Buu-Hoï Annie, Acar J. F. Typhoid fever due to a Salmonella typhi strain of reduced susceptibility to fluoroquinolones. Clin Microbiol Infect. 1997;3(5):541–544. doi: 10.1111/j.1469-0691.1997.tb00304.x. [DOI] [PubMed] [Google Scholar]
  14. Le Lostec Zoe, Fegueux S., Jouve P., Cheron M., Mornet P., Boisivon A. Reduced susceptibility to quinolones in Salmonella typhi acquired in Europe: a clinical failure of treatment. Clin Microbiol Infect. 1997;3(5):576–577. doi: 10.1111/j.1469-0691.1997.tb00313.x. [DOI] [PubMed] [Google Scholar]
  15. Levy S. B. Multidrug resistance--a sign of the times. N Engl J Med. 1998 May 7;338(19):1376–1378. doi: 10.1056/NEJM199805073381909. [DOI] [PubMed] [Google Scholar]
  16. Martínez-Martínez L., Pascual A., Jacoby G. A. Quinolone resistance from a transferable plasmid. Lancet. 1998 Mar 14;351(9105):797–799. doi: 10.1016/S0140-6736(97)07322-4. [DOI] [PubMed] [Google Scholar]
  17. McCarron B., Love W. C. Acalculous nontyphoidal salmonellal cholecystitis requiring surgical intervention despite ciprofloxacin therapy: report of three cases. Clin Infect Dis. 1997 Apr;24(4):707–709. doi: 10.1093/clind/24.4.707. [DOI] [PubMed] [Google Scholar]
  18. McKellar Q., Gibson I., Monteiro A., Bregante M. Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. Antimicrob Agents Chemother. 1999 Aug;43(8):1988–1992. doi: 10.1128/aac.43.8.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Medders W. M., Wooley R. E., Gibbs P. S., Shotts E. B., Brown J. Mutation rate of avian intestinal coliform bacteria when pressured with fluoroquinolones. Avian Dis. 1998 Jan-Mar;42(1):146–153. [PubMed] [Google Scholar]
  20. Mølbak K., Baggesen D. L., Aarestrup F. M., Ebbesen J. M., Engberg J., Frydendahl K., Gerner-Smidt P., Petersen A. M., Wegener H. C. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med. 1999 Nov 4;341(19):1420–1425. doi: 10.1056/NEJM199911043411902. [DOI] [PubMed] [Google Scholar]
  21. O'Brien T. F., Stelling J. M. WHONET: an information system for monitoring antimicrobial resistance. Emerg Infect Dis. 1995 Apr-Jun;1(2):66–66. doi: 10.3201/eid0102.950209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ouabdesselam S., Tankovic J., Soussy C. J. Quinolone resistance mutations in the gyrA gene of clinical isolates of Salmonella. Microb Drug Resist. 1996 Fall;2(3):299–302. doi: 10.1089/mdr.1996.2.299. [DOI] [PubMed] [Google Scholar]
  23. Pers C., Søgaard P., Pallesen L. Selection of multiple resistance in Salmonella enteritidis during treatment with ciprofloxacin. Scand J Infect Dis. 1996;28(5):529–531. doi: 10.3109/00365549609037954. [DOI] [PubMed] [Google Scholar]
  24. Piddock L. J., Griggs D. J., Hall M. C., Jin Y. F. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother. 1993 Apr;37(4):662–666. doi: 10.1128/aac.37.4.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Piddock L. J., Ricci V., McLaren I., Griggs D. J. Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom. J Antimicrob Chemother. 1998 Jun;41(6):635–641. doi: 10.1093/jac/41.6.635. [DOI] [PubMed] [Google Scholar]
  26. Prats G., Mirelis B., Llovet T., Muñoz C., Miró E., Navarro F. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob Agents Chemother. 2000 May;44(5):1140–1145. doi: 10.1128/aac.44.5.1140-1145.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ronald A. R., Turck M., Petersdorf R. G. A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med. 1966 Nov 17;275(20):1081–1089. doi: 10.1056/NEJM196611172752001. [DOI] [PubMed] [Google Scholar]
  28. Rowe B., Ward L. R., Threlfall E. J. Ciprofloxacin-resistant Salmonella typhi in the UK. Lancet. 1995 Nov 11;346(8985):1302–1302. doi: 10.1016/s0140-6736(95)91906-6. [DOI] [PubMed] [Google Scholar]
  29. Smith K. E., Besser J. M., Hedberg C. W., Leano F. T., Bender J. B., Wicklund J. H., Johnson B. P., Moore K. A., Osterholm M. T. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med. 1999 May 20;340(20):1525–1532. doi: 10.1056/NEJM199905203402001. [DOI] [PubMed] [Google Scholar]
  30. Stelling J. M., O'Brien T. F. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis. 1997 Jan;24 (Suppl 1):S157–S168. doi: 10.1093/clinids/24.supplement_1.s157. [DOI] [PubMed] [Google Scholar]
  31. Sáenz Y., Zarazaga M., Lantero M., Gastanares M. J., Baquero F., Torres C. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob Agents Chemother. 2000 Feb;44(2):267–271. doi: 10.1128/aac.44.2.267-271.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Threlfall E. J., Frost J. A., Ward L. R., Rowe B. Increasing spectrum of resistance in multiresistant Salmonella typhimurium. Lancet. 1996 Apr 13;347(9007):1053–1054. doi: 10.1016/s0140-6736(96)90199-3. [DOI] [PubMed] [Google Scholar]
  33. Vasallo F. J., Martín-Rabadán P., Alcalá L., García-Lechuz J. M., Rodríguez-Créixems M., Bouza E. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis. 1998 Feb;26(2):535–536. doi: 10.1086/517087. [DOI] [PubMed] [Google Scholar]
  34. Wain J., Hoa N. T., Chinh N. T., Vinh H., Everett M. J., Diep T. S., Day N. P., Solomon T., White N. J., Piddock L. J. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997 Dec;25(6):1404–1410. doi: 10.1086/516128. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES